Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diflucortolone→

Diflucortolone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2607-06-9
Molecular formula
C22H28F2O4
Molecular weight
394.5 g/mol
Drug class
Topical glucocorticoidcorticosteroid receptor agonist
Mechanism of action
Activates intracellular glucocorticoid receptors in skin, regulating inflammatory gene expression and suppressing cytokine production, leukocyte migration and other immune responses.
Indications / reported uses
  • Topical treatment of corticosteroid-responsive inflammatory dermatoses, including eczema and dermatitis, using the appropriate strength and formulation; combination products containing an antifungal have separate combination-specific indications

Sources: UK product information — Diflucortolone-containing products · NLM MeSH — Diflucortolone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Diflucortolone Environmental Risk Assessment (ERA) (the Diflucortolone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.